According to reports, ANTENGENE-B (06996) saw its shares rise over 6%, currently at a 6.16% increase, trading at HKD 5.17 with a turnover of HKD 12.1859 million. On October 20, ANTENGENE announced the latest results of its Phase I/II clinical study for the CLDN18.2 antibody-drug conjugate (ADC) ATG-022 at the European Society for Medical Oncology Annual Meeting (ESMO2025) held in Berlin, Germany. ATG-022 demonstrated good safety and significant anti-tumor activity across patients with varying expression levels of CLDN18.2 in gastric and gastroesophageal junction cancers (GC/GEJC), supporting further clinical development in patients expressing different levels of CLDN18.2. Additionally, preliminary efficacy was also observed in other non-gastrointestinal tumors, with related data set to be published at future academic conferences. Notably, the safety data from the 2.4mg/kg dosing group was positive, while the 1.8mg/kg group showed even better safety and tolerability profiles. The company indicated that this provides a strong basis for advancing the combination of ATG-022 with immune checkpoint inhibitors and chemotherapy in frontline treatment, significantly expanding its clinical applications and commercialization potential. Currently, the Phase I dose expansion study of ATG-022 is progressing smoothly in Mainland China and Australia. Meanwhile, the company is actively moving forward with clinical research preparations for combination therapies to further accelerate its clinical development process.